Company profile
Leef Brands Inc.
OTC: LEEEF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCReports USD
#481 of 1,418 Healthcare companies by revenue69th-percentile growth
EA Score
57CFH 56DQ —GM 67SS 47
v0.1 · 45/100 weight · provisional
↑ Piotroski F, growth stability · ↓ listing tenure, balance-sheet leverage
Methodology →Revenue TTM
$33.3M
Rev growth YoY (TTM)
+8.4%
Net income (FY)
-$17.9M
Employees
90
as of 2026-08-20
Market cap
$42.0M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$35.4M$35.4M2025
Net income-$17.9M-$17.9M2025
Operating income-$5.3M-$5.3M2025
Total assets$36.3M$36.3M2025
Liabilities$44.6M$44.6M2025
Equity-$8.3M-$8.3M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Leef Brands Inc.’s revenue?
Leef Brands Inc. booked $35.4M in FY2025 revenue, growing 24% year over year — faster than most Healthcare companies we track, at a -50.7% net margin.
Peers · Healthcare
C4 Therapeutics, Inc.49DEarth Science Tech, Inc.69BVerrica Pharmaceuticals Inc.51DSenseonics Holdings, Inc.57CX4 Pharmaceuticals, Inc.51DPrecision BioSciences, Inc.46DKey facts
CEOMicah Anderson
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeOTC: LEEEF
Employees90
IPO date2021-01-08
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.